Home › Funds › Stokes Capital Advisors, LLC › GILD

Stokes Capital Advisors, LLC position in GILD

GILEAD SCIENCES INC · Health Care

Stokes Capital Advisors, LLC reported holding 36,264 shares of GILD (GILEAD SCIENCES INC) in its Q3 2026 13F filing — a position valued at US$5.4M, representing 1.19% of its reported portfolio and ranking #34 among its reported holdings. Stokes Capital Advisors, LLC has disclosed GILD holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

Latest position (Q3 2026)36.26K sh
Reported value held$5.41M
Portfolio Weight1.19%
First reportedQ1 2026
Last changeAdd
Updated2026-10-09

Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR

How Stokes Capital Advisors, LLC's GILD position evolved

Stokes Capital Advisors, LLC first disclosed a stake in GILD in Q1 2026 at 2,025 shares (US$282K). The position peaked in Q3 2026 at 36,264 shares, worth US$5.4M. Across 3 filings, Stokes Capital Advisors, LLC increased the stake 2 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 36,264 shares valued at US$5.4M — an increase of 894 shares quarter over quarter.. Notable position changes include a 1647% increase in Q2 2026 (shares rose 18% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q1 2026 2.02K $282.23K New
Q2 2026 35.37K $4.47M Add
Q3 2026 36.26K $5.41M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GILD and 13F data

GILD (GILEAD SCIENCES INC) is a Health Care company. 35 other funds we track also report a position in GILD — the largest reported positions include Fidelity Management & Research (FMR) (US$8.45B), Capital World Investors (US$5.18B), Capital World Investors (US$5.18B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GILD

All GILD fund holders →

FAQ

How long has Stokes Capital Advisors, LLC held GILD?

Stokes Capital Advisors, LLC has disclosed GILD holdings in 3 of the last 3 reported quarters, going back to Q1 2026.

What is Stokes Capital Advisors, LLC's current position in GILD?

As of Q3 2026, Stokes Capital Advisors, LLC holds 36.26K shares of GILD (GILEAD SCIENCES INC), valued at $5.41M, representing 1.19% of its reported portfolio and ranking #34.

Has Stokes Capital Advisors, LLC been buying or selling GILD?

In the latest 13F filing (Q3 2026), Stokes Capital Advisors, LLC increased its position in GILD. The position peaked in Q3 2026 at 36.26K shares.

Which other funds hold GILD?

Other major institutional holders of GILD include Fidelity Management & Research (FMR), Capital World Investors, Capital World Investors, among 35 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.